The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Mark A. Tomai sits on this spectrum.
This scientist: 132 publications — 18th percentile
18% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Mark A. Tomai sits on this spectrum.
This scientist: 60 D-Index — 41st percentile
41% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
Mark A. Tomai is affiliated with 3M in the United States. Their research primarily spans Medicine and Immunology and Microbiology, with significant focus in related subfields such as Immunology, Infectious Diseases, Virology, Epidemiology, and Molecular Biology.
The scientist's work encompasses a range of topics centered on immune system mechanisms and infectious diseases. Main research topics include SARS-CoV-2 and COVID-19 research, HIV research and treatment, immune cell function and interaction, immunotherapy and immune responses, T-cell and B-cell immunology, vaccines and immunoinformatics approaches, and immune response and inflammation.
Mark A. Tomai has contributed to multiple papers in notable publication venues, including bioRxiv (Cold Spring Harbor Laboratory), Nature Communications, Science Immunology, Science Translational Medicine, and Frontiers in Immunology.
Representative papers include:
Frequent co-authors collaborating with Mark A. Tomai include:
Publication venues where their work frequently appears are:
Main fields of study evident from their publication record are:
Key subfields contributing to their research output include:
The researcher's work reflects a focus on vaccine development, immune response modulation, and combating infectious diseases such as HIV and COVID-19 through immunological approaches and adjuvant innovation.
Keith B. Gorden;Kevin S. Gorski;Sheila J. Gibson;Ross M. Kedl
Sheila J Gibson;Jana M Lindh;Tony R Riter;Raymond M Gleason
Hirotake Suzuki;Binghe Wang;Gulnar M Shivji;Paola Toto
Stephen K. Tyring;Istvan Arany;Margaret A. Stanley;Mark A. Tomai
Traci L. Testerman;John F. Gerster;Linda M. Imbertson;Michael J. Reiter
Tamara L. Wagner;Cory L. Ahonen;Aimee M. Couture;Sheila J. Gibson
John L. Chollet;Michael J. Jozwiakowski;Kenneth R. Phares;Michael J. Reiter
John P Vasilakos;Mark A Tomai
Bernstein David I;Harrison Christopher J;Miller Richard L;Tomai Mark A
Beaurline Joseph M;Roddy Patrick J;Tomai Mark A
Kevin O. Saunders;Esther Lee;Robert Parks;David R. Martinez
John P. Vasilakos;Rose M.A. Smith;Sheila J. Gibson;Jana M. Lindh
Linda M Imbertson;Joseph M Beaurline;Aimee M Couture;Sheila J Gibson
Michael J. Reiter;Traci L. Testerman;Richard L. Miller;Charles E. Weeks
K Megyeri;W C Au;I Rosztoczy;N B Raj
Robert P. Burns;Barbara Ferbel;Mark Tomai;Richard Miller
Richard L Miller;Tze-Chiang Meng;Mark A Tomai
Kevin S. Gorski;Emily L. Waller;Jacqueline Bjornton-Severson;John A. Hanten
Mark A. Tomai;Sheila J. Gibson;Linda M. Imbertson;Richard L. Miller
Sheila J. Gibson;Linda M. Imbertson;Tamara L. Wagner;Traci L. Testerman
If you think any of the details on this page are incorrect, let us know.
University of Lille
University of Science and Technology of China
University of Melbourne
University of Copenhagen
University of Oklahoma
University of Vienna
Federal University of Rio de Janeiro
Jet Propulsion Lab
VTT Technical Research Centre of Finland
Chinese University of Hong Kong
University of Florida
Stanford University
University of Zagreb
University Of Thessaly
University of Pittsburgh
University of Milan
